Results 151 to 160 of about 119,184 (308)

Therapeutic hepatitis B vaccine employing DNA prime - MVA boost scheme requires additional priming with recombinant HBsAg to elicit an adequate antibody response. [PDF]

Front Immunol
Kerth HA, Kächele M, Müller N, Singh S, Tulessin M, Sacherl J, Ates Öz E, Su J, Bester R, Miko S, Steiger K, Mogler C, Busch DH, Wettengel JM, Protzer U, Kosinska AD.   +15 more
europepmc   +1 more source

Fast Quantitative Evaluation of the Amelioration Effect in MASLD During Semaglutide Treatment Using Ultrasound‐Derived Fat Fraction and Fat‐to‐Muscle Ratio

Portal Hypertension &Cirrhosis, EarlyView.
Metabolic dysfunction‐associated steatotic liver disease (MASLD) is a chronic liver disease. Research into a feasible, rapid, and effective assessment method is crucial for evaluating the therapeutic effects of semaglutide in MASLD. This prospective study utilized ultrasound‐derived fat fraction measurement and fat‐to‐muscle ratio to evaluate hepatic ...
Yunlin Huang, Ruping Yang, Ying Wang, Xiu‐Yun Lu, Li Wei, Rui Cheng, Juan Cheng, Yijie Qiu, Shiwen Wang, Bo Li, Yi Dong   +10 more
wiley   +1 more source

Harnessing conserved epitopes and multivalent antigen strategies for vaccine design: Lessons learned and opportunities. [PDF]

Hum Vaccin Immunother
Adjei-Gati E, Quaye CNO, Lamptey PO, Oklu LD, Kwofie JN, Hafiz YA, Kusi KA.   +6 more
europepmc   +1 more source

A review of adult and pediatric post-transplant liver pathology. [PDF]

, 1987
Demetris, AJ, Jaffe, R, Starzl, TE
core  

From HBV to MASLD Cirrhosis: Mechanistic Insights and Therapeutic Strategies

Portal Hypertension &Cirrhosis, EarlyView.
This review examines the epidemiological shift from hepatitis B virus (HBV) to metabolic dysfunction‐associated steatotic liver disease (MASLD) as the leading cause of cirrhosis globally. It highlights the distinct pathogenic mechanisms between HBV and MASLD cirrhosis and discusses evolving diagnostic tools and therapeutic strategies tailored to the ...
Hanqi Yu, Hongfan Ding, Yang Huang, Haoze Cao, Yuan Ding, Weilin Wang   +5 more
wiley   +1 more source

Hepatitis B Core-Related Antigen Level Predicts Disease Progression in the Gray Zone Hepatitis B Patients. [PDF]

J Med Virol
Suzuki T, Matsuura K, Inoue T, Kawamura H, Fujiwara K, Kataoka H, Tanaka Y.   +6 more
europepmc   +1 more source

The Safety of Interferon‐Based Therapies in Chronic Hepatitis B Patients With Compensatory Cirrhosis

Portal Hypertension &Cirrhosis, EarlyView.
While nucleos(t)ide analog (Nuc) therapy is the standard for chronic hepatitis B, pegylated interferon‐alpha (Peg‐IFN‐α) provides unique advantages, including finite treatment duration and long‐term benefits. However, its use in patients with compensated cirrhosis remains limited due to persistent safety concerns about potential decompensation and ...
Qiran Zhang, Taoran Geng, Ruirui You, Huiling Xiang, Ying Guo, Xiaohong Gao, Guojun Li, Qun Zhang, Xiaoping Wu, Haifang Cao, Wenhua Zhang, Jia Shang, Jiawei Geng, Lihong Qu, Shuilin Sun, Xiulan Xue, Rui Zhao, Lihua Zhong, Guohong Ge, Yanbin Wang, Jianqi Lian, Ming Liang, Qing Ye, Xiaoyan Wang, Xiaoqing Guo, Dan Xu, Yiqi Yu, Feng Sun, Chao Qiu, Jiming Zhang, Yuxian Huang, Wenhong Zhang, Xiaolong Qi   +32 more
wiley   +1 more source

Trends in clinical intervention practice for preventing mother-to-child transmission of hepatitis B virus in Guangdong Province, 2021-2023. [PDF]

Hum Vaccin Immunother
Gao S, Xie T, Cai M, Su M, Zhao T, Zhang X, Zhang S, Wang M, Xu Q, Cheng Y, Cui F, Liu F.   +11 more
europepmc   +1 more source

Current Cell/Organoid and Animal Models for Primary Sclerosing Cholangitis

Portal Hypertension &Cirrhosis, EarlyView.
Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease with limited therapeutic options and a marked risk of progression to biliary fibrosis, cirrhosis, and malignancy. Progress in PSC research has been hindered by the lack of models that faithfully recapitulate the complex biliary microenvironment and disease heterogeneity ...
Qigu Yao, Sheng Cheng, Qiaoling Pan, Jiong Yu, Hongcui Cao   +4 more
wiley   +1 more source

Hepatitis B-Virus-e-Antigen [PDF]

, 2019
openaire   +1 more source